These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 25246230)
1. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Marshall NR; Hassiotis S; King B; Rozaklis T; Trim PJ; Duplock SK; Winner LK; Beard H; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM Exp Neurol; 2015 Jan; 263():79-90. PubMed ID: 25246230 [TBL] [Abstract][Full Text] [Related]
2. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416 [TBL] [Abstract][Full Text] [Related]
3. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice. Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516 [TBL] [Abstract][Full Text] [Related]
4. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study. Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666 [TBL] [Abstract][Full Text] [Related]
5. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Hemsley KM; King B; Hopwood JJ Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757 [TBL] [Abstract][Full Text] [Related]
6. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091 [TBL] [Abstract][Full Text] [Related]
13. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972 [TBL] [Abstract][Full Text] [Related]
14. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain. Jolly RD; Marshall NR; Perrott MR; Dittmer KE; Hemsley KM; Beard H Neuropathol Appl Neurobiol; 2011 Jun; 37(4):414-22. PubMed ID: 21175738 [TBL] [Abstract][Full Text] [Related]
15. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Savas PS; Hemsley KM; Hopwood JJ Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125 [TBL] [Abstract][Full Text] [Related]
16. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431 [TBL] [Abstract][Full Text] [Related]
17. Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain. Beard H; Hassiotis S; Luck AJ; Rozaklis T; Hopwood JJ; Hemsley KM JIMD Rep; 2016; 29():59-68. PubMed ID: 26620043 [TBL] [Abstract][Full Text] [Related]
18. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA). Hassiotis S; Jolly RD; Hemsley KM Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402 [TBL] [Abstract][Full Text] [Related]
19. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Dickson PI Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323 [TBL] [Abstract][Full Text] [Related]
20. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. King B; Savas P; Fuller M; Hopwood J; Hemsley K Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]